Sharl Azar is an Oncology physician affiliated with Harvard University. OpenAlex indexes 12 publications with 745 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Boston, MA 021142621
Telephone
800-711-4644Provider last certified this registry record 8 Mar 2023.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Agios Pharmaceuticals, Inc.Program year20253 payments
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20252 payments
- Novo Nordisk IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
83.9%Opioid Agonist68.7%Oxycodone Hcl40%Morphine Sulfate Er25%Methadone Hcl14%Morphine Sulfate11%Hydromorphone Hcl10%Part D<11 patientsPartial Opioid Agonist8.3%Buprenorphine-Naloxone100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
12.2%Antimetabolite12.2%Hydroxyurea100%Part D≥17 patientsBlood & clotting
3.9%Factor Xa inhibitor3.9%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Out of Reach: Understanding Resource Barriers to Gene Therapy for Pediatric Patients With Sickle Cell Disease
Pediatric Blood & Cancer
2026 - Impact of Integrated Primary Care on Care Utilization and Preventative Care for Patients with Sickle Cell Disease
Journal of General Internal Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”